Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in J Thorac Oncol

Retrieve available abstracts of 443 articles:
HTML format
Text format



Single Articles


    May 2017
  1. FELLER-KOPMAN D, Liu S, Geisler BP, DeCamp MM, et al
    Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30364.
    PubMed     Text format     Abstract available


  2. CRESSMAN S, Peacock SJ, Tammemagi MC, Evans WK, et al
    The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30354.
    PubMed     Text format     Abstract available


  3. ADAMS MN, Burgess JT, He Y, Gately K, et al
    Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer.
    J Thorac Oncol. 2017 May 6. pii: S1556-0864(17)30351.
    PubMed     Text format     Abstract available


  4. GONG X, Li X, Jiang T, Xie H, et al
    Combined Radiotherapy and anti-PD-L1 antibody Synergistically Enhances Anti-tumor Effect in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 May 3. pii: S1556-0864(17)30343.
    PubMed     Text format     Abstract available


  5. MIYAUCHI E, Ichinose M, Inoue A
    Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.
    J Thorac Oncol. 2017;12:e59-e61.
    PubMed     Text format    


  6. DAHELE M, Damhuis R
    The Relationship between Histology, Stage, and Type of Treatment in Patients with Early-Stage Lung Cancer.
    J Thorac Oncol. 2017;12:e58-e59.
    PubMed     Text format    


  7. RICCIUTI B, Metro G, Baglivo S, Colabrese D, et al
    Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e51-e55.
    PubMed     Text format    


  8. OGATA H, Yamamoto Y, Harada T, Nakanishi Y, et al
    Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e46-e47.
    PubMed     Text format    


  9. ABDUL KARIM L, Wang P, Chahine J, Kallakury B, et al
    Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress.
    J Thorac Oncol. 2017;12:e45.
    PubMed     Text format    


    April 2017
  10. CHANSKY K, Detterbeck FC, Nicholson AG, Rusch VW, et al
    The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30340.
    PubMed     Text format     Abstract available


  11. RECK M, Blais N, Juhasz E, Gorbunova V, et al
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30338.
    PubMed     Text format     Abstract available


  12. JENKINS S, C-H Yang J, Ramalingam SS, Yu K, et al
    Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 17. pii: S1556-0864(17)30280.
    PubMed     Text format     Abstract available


  13. SOO RA, Adjei AA
    Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.
    J Thorac Oncol. 2017;12:602-606.
    PubMed     Text format    


  14. GARDNER EE, Poirier JT, Rudin CM
    Histone Code Aberrancies in Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:599-601.
    PubMed     Text format    


    March 2017
  15. SENAN S, Louie AV
    Correlation, Causation and Confounding-What Is the True Risk of Lung Cancer following Breast Cancer Radiotherapy?
    J Thorac Oncol. 2017 Mar 22. pii: S1556-0864(17)30127.
    PubMed     Text format    


  16. TEKATLI H, van 't Hof S, Nossent EJ, Dahele M, et al
    Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    J Thorac Oncol. 2017 Mar 7. pii: S1556-0864(17)30180.
    PubMed     Text format     Abstract available


  17. PELED N, Roisman LC, Miron B, Pfeffer R, et al
    Sub-Clonal Therapy by two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-mutated Lung Cancer.
    J Thorac Oncol. 2017 Mar 7. pii: S1556-0864(17)30182.
    PubMed     Text format    


  18. YORK E, Varella-Garcia M, Bang TJ, Aisner DL, et al
    Tolerable and effective combination of full dose crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR mutant non-small cell lung cancer.
    J Thorac Oncol. 2017 Mar 5. pii: S1556-0864(17)30167.
    PubMed     Text format    


  19. DICKHOFF C, Senan S, Dahele M
    Radical-Intent Treatment of Lung Cancer after Prior Thoracic Radiotherapy.
    J Thorac Oncol. 2017;12:e26-e27.
    PubMed     Text format    


  20. VERNON J, Hanna WC
    Response to Screening for Brain Metastases in Resectable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e22.
    PubMed     Text format    


  21. HENDRIKS LE, Hochstenbag M, Dingemans AM
    Screening for Brain Metastases in Resectable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e21.
    PubMed     Text format    


  22. NOTSUDA H, Bradbury PA, Tsao MS
    HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy.
    J Thorac Oncol. 2017;12:422-424.
    PubMed     Text format    


  23. PIOTROWSKA Z, Sequist LV
    Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.
    J Thorac Oncol. 2017;12:419-421.
    PubMed     Text format    


  24. SUN B, Brooks ED, Komaki R, Liao Z, et al
    Long-Term Outcomes of Salvage Stereotactic Ablation Radiotherapy for Isolated Lung Recurrence of Non-Small-Cell Lung Cancer: A Phase II Clinical Trial.
    J Thorac Oncol. 2017 Mar 1. pii: S1556-0864(17)30129.
    PubMed     Text format     Abstract available


    February 2017
  25. HATTORI A, Matsunaga T, Hayashi T, Takamochi K, et al
    Prognostic Impact of the Findings on Thin-Section Computed Tomography in Patients with Subcentimeter Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Feb 28. pii: S1556-0864(17)30126.
    PubMed     Text format     Abstract available


  26. IWAMA E, Goto Y, Murakami H, Harada T, et al
    Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401).
    J Thorac Oncol. 2017 Feb 23. pii: S1556-0864(17)30123.
    PubMed     Text format     Abstract available


  27. SUDA K, Murakami I, Yu H, Kim J, et al
    Heterogeneity in immune marker expression after acquisition of resistance to EGFR kinase inhibitors: analysis of a case with small cell lung cancer transformation.
    J Thorac Oncol. 2017 Feb 10. pii: S1556-0864(17)30098.
    PubMed     Text format     Abstract available


  28. GUIBERT N, Barlesi F, Descourt R, Lena H, et al
    Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
    J Thorac Oncol. 2017 Feb 9. pii: S1556-0864(17)30097.
    PubMed     Text format     Abstract available


  29. CHUANG JC, Stehr H, Liang Y, Das M, et al
    ERBB2-mutated metastatic non-small cell lung cancer: response and resistance to targeted therapies.
    J Thorac Oncol. 2017 Feb 3. pii: S1556-0864(17)30090.
    PubMed     Text format     Abstract available


  30. SAWABATA N
    Cluster Circulating Tumor Cell Is Crucial in Surgically Resected Lung Cancer.
    J Thorac Oncol. 2017;12:e18-e19.
    PubMed     Text format    


  31. VELCHETI V, Khunger M, Abazeed ME
    Novel EGFR Exon 18 (G721R) Mutation in a Patient with Non-Small Cell Lung Carcinoma with Lack of Response to Afatinib.
    J Thorac Oncol. 2017;12:e16-e18.
    PubMed     Text format    


  32. VELCHETI V, Thawani R, Khunger M, Mukhopadhyay S, et al
    FRMD4A/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
    J Thorac Oncol. 2017;12:e15-e16.
    PubMed     Text format    


  33. LE PECHOUX C
    Prophylactic Cranial Irradiation or No Prophylactic Cranial Irradiation after Adjuvant Chemotherapy in Resected Small Cell Lung Cancer?
    J Thorac Oncol. 2017;12:173-175.
    PubMed     Text format    


  34. BAGGSTROM MQ, Socinski MA, Wang XF, Gu L, et al
    Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced Stage IIIB/IV Non-small cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study - CALGB 30607 (Alliance).
    J Thorac Oncol. 2017 Feb 1. pii: S1556-0864(17)30089.
    PubMed     Text format     Abstract available


    January 2017
  35. HUANG YJ, Huang TW, Lin FH, Chung CH, et al
    Radiation Therapy for Invasive Breast Cancer Increases the Risk of Second Primary Lung Cancer: A Nationwide Population-based Cohort Analysis.
    J Thorac Oncol. 2017 Jan 31. pii: S1556-0864(17)30045.
    PubMed     Text format     Abstract available


  36. HE Y, Yu H, Rozeboom L, Rivard CJ, et al
    LAG-3 Protein Expression in Non-small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    J Thorac Oncol. 2017 Jan 26. pii: S1556-0864(17)30043.
    PubMed     Text format     Abstract available


  37. DAI J, Liu M, Swensen SJ, Stoddard SM, et al
    Regional Emphysema Score Predicting Overall Survival, Quality of Life and Pulmonary Function Recovery in Early-stage Lung Cancer Patients.
    J Thorac Oncol. 2017 Jan 23. pii: S1556-0864(17)30040.
    PubMed     Text format     Abstract available


  38. DAVID EA, Daly ME, Li CS, Chiu CL, et al
    Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis.
    J Thorac Oncol. 2017 Jan 18. pii: S1556-0864(16)33476.
    PubMed     Text format     Abstract available


  39. ZHU M, Geng L, Shen W, Wang Y, et al
    Exome-wide association study identifies low-frequency coding variants in 2p23.2 and 7p11.2 associated with survival of non-small cell lung cancer patients.
    J Thorac Oncol. 2017 Jan 16. pii: S1556-0864(17)30013.
    PubMed     Text format     Abstract available


  40. SCHILD SE, Hillman SL, Tan AD, Ross HJ, et al
    Long-Terms Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (ALLIANCE).
    J Thorac Oncol. 2017 Jan 12. pii: S1556-0864(17)30005.
    PubMed     Text format     Abstract available


  41. KARASAKI T, Nagayama K, Kuwano H, Nitadori JI, et al
    An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer.
    J Thorac Oncol. 2017 Jan 11. pii: S1556-0864(17)30008.
    PubMed     Text format     Abstract available


  42. LIN JJ, Ritterhouse LL, Ali SM, Bailey M, et al
    ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer.
    J Thorac Oncol. 2017 Jan 11. pii: S1556-0864(17)30007.
    PubMed     Text format     Abstract available


  43. YAP TA, Popat S
    Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?
    J Thorac Oncol. 2017;12:12-14.
    PubMed     Text format    


    December 2016
  44. CASTELLANOS E, Feld E, Horn L
    Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Dec 22. pii: S1556-0864(16)33604.
    PubMed     Text format     Abstract available


  45. USUI Y, Udagawa H, Matsumoto S, Imai K, et al
    Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Dec 22. pii: S1556-0864(16)33605.
    PubMed     Text format    


  46. PETERS S, Stahel RA, Dafni U, Aix SP, et al
    Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoraci
    J Thorac Oncol. 2016 Dec 22. pii: S1556-0864(16)33607.
    PubMed     Text format     Abstract available


  47. YAMAMOTO N, Miyamoto T, Nakajima M, Karube M, et al
    A dose escalation clinical trial of single-fraction carbon-ion radiotherapy for peripheral stage I non-small-cell lung cancer.
    J Thorac Oncol. 2016 Dec 19. pii: S1556-0864(16)33581.
    PubMed     Text format     Abstract available


  48. SCHMID S, Gautschi O, Rothschild S, Mark M, et al
    Clinical Outcome of ALK -Positive Non-Small Cell Lung Cancer (NSCLC) Patients with de novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKI).
    J Thorac Oncol. 2016 Dec 19. pii: S1556-0864(16)33560.
    PubMed     Text format     Abstract available


  49. DING PN, Lord SJ, Gebski V, Links M, et al
    Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib and afatinib in advanced EGFR-mutated non-small-cell lung cancer.
    J Thorac Oncol. 2016 Dec 19. pii: S1556-0864(16)33582.
    PubMed     Text format     Abstract available


  50. MAO X, Zhang Z, Zheng X, Xie F, et al
    Capture-based targeted ultra-deep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA releasing capability in advanced lung cancer.
    J Thorac Oncol. 2016 Dec 19. pii: S1556-0864(16)33575.
    PubMed     Text format     Abstract available


  51. AUGERT A, Zhang Q, Bates B, Cui M, et al
    Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D/MLL2 : CALGB 151111 (Alliance).
    J Thorac Oncol. 2016 Dec 19. pii: S1556-0864(16)33580.
    PubMed     Text format     Abstract available


  52. THUNNISSEN E, Borczuk AC, Flieder DB, Witte B, et al
    The use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and its Differential Diagnosis. An international reproducibility study in a demanding set of cases.
    J Thorac Oncol. 2016 Dec 17. pii: S1556-0864(16)33572.
    PubMed     Text format     Abstract available


  53. MITIN T, Thomas CR Jr
    Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer: Authors' Reply.
    J Thorac Oncol. 2016;11:e152.
    PubMed     Text format    


  54. KIM YH
    Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2016;11:e151-e152.
    PubMed     Text format    


    November 2016
  55. HIRSCH FR, McElhinny A, Stanforth D, Ranger-Moore J, et al
    PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the "Blueprint PD-L1 IHC Assay Comparison Project".
    J Thorac Oncol. 2016 Nov 29. pii: S1556-0864(16)33536.
    PubMed     Text format     Abstract available


  56. SONI PD, Boonstra PS, Schipper MJ, Bazzi L, et al
    Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer.
    J Thorac Oncol. 2016 Nov 26. pii: S1556-0864(16)33535.
    PubMed     Text format     Abstract available


  57. GANDARA DR, Leighl N, Delord JP, Barlesi F, et al
    A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Nov 19. pii: S1556-0864(16)33473.
    PubMed     Text format     Abstract available


  58. SHIN J, Keam B, Kim M, Park YS, et al
    Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Nov 17. pii: S1556-0864(16)33457.
    PubMed     Text format     Abstract available


  59. ROZENBLUM AB, Ilouze M, Dudnik E, Dvir A, et al
    Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    J Thorac Oncol. 2016 Nov 9. pii: S1556-0864(16)31241.
    PubMed     Text format     Abstract available


  60. PYO KH, Lim SM, Kim HR, Sung YH, et al
    Establishment of a conditional transgenic mouse model recapitulating EML4-ALK-positive human non-small cell lung cancer.
    J Thorac Oncol. 2016 Nov 8. pii: S1556-0864(16)31242.
    PubMed     Text format     Abstract available


  61. LUO X, Zang X, Yang L, Huang J, et al
    Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis.
    J Thorac Oncol. 2016 Nov 4. pii: S1556-0864(16)31236.
    PubMed     Text format     Abstract available


  62. CHAO HH, Berman AT, Simone CB 2nd, Ciunci C, et al
    Multi-institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Nov 4. pii: S1556-0864(16)31237.
    PubMed     Text format     Abstract available


  63. KELLY RJ, Smith TJ
    Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis.
    J Thorac Oncol. 2016;11:1814-1816.
    PubMed     Text format    


    October 2016
  64. DRILON A, Cappuzzo F, Ignatius Ou SH, Camidge DR, et al
    Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
    J Thorac Oncol. 2016 Oct 26. pii: S1556-0864(16)31179.
    PubMed     Text format     Abstract available


  65. MYSIKOVA D, Adkins I, Nada H, Ondrej P, et al
    Case-control study: Smoking history affects the production of tumor antigen specific antibodies NY-ESO-1 in patients with lung cancer in comparison with cancer disease free group.
    J Thorac Oncol. 2016 Oct 25. pii: S1556-0864(16)31176.
    PubMed     Text format     Abstract available


  66. MATEU-JIMENEZ M, Curull V, Pijuan L, Sanchez-Font A, et al
    Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer: Influence of Underlying Chronic Respiratory Disease.
    J Thorac Oncol. 2016 Oct 25. pii: S1556-0864(16)31177.
    PubMed     Text format     Abstract available


  67. KIM C, Hoang CD, Kesarwala AH, Schrump DS, et al
    Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2016 Oct 22. pii: S1556-0864(16)31175.
    PubMed     Text format     Abstract available


  68. LEE CK, Man J, Lord S, Links M, et al
    Brief report: Checkpoint inhibitors in metastatic EGFR mutated non-small-cell lung cancer - a meta-analysis.
    J Thorac Oncol. 2016 Oct 17. pii: S1556-0864(16)31167.
    PubMed     Text format     Abstract available


  69. HERSKOVIC A, Mauer E, Christos P, Nagar H, et al
    Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database.
    J Thorac Oncol. 2016 Oct 13. pii: S1556-0864(16)31145.
    PubMed     Text format     Abstract available


  70. SPEIRS CK, DeWees TA, Rehman S, Molotievschi A, et al
    Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer.
    J Thorac Oncol. 2016 Oct 12. pii: S1556-0864(16)31144.
    PubMed     Text format     Abstract available


  71. XU J, Yang H, Fu X, Jin B, et al
    Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Oct 7. pii: S1556-0864(16)31139.
    PubMed     Text format     Abstract available


  72. GAO SJ, Corso CD, Wang EH, Blasberg JD, et al
    Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Oct 5. pii: S1556-0864(16)31072.
    PubMed     Text format     Abstract available


  73. LICKER M, Karenovics W, Diaper J, Fresard I, et al
    Short-term preoperative high-intensity interval training in patients awaiting lung cancer surgery: a randomized controlled trial.
    J Thorac Oncol. 2016 Oct 5. pii: S1556-0864(16)31075.
    PubMed     Text format     Abstract available


  74. LUVIAN-MORALES J, De La Torre-Vallejo M, Gonzalez-Ling A, Arrieta O, et al
    P2.29: An Approach to Ensure Adequate Intake of Nutrients for Patients With Lung Cancer: Track: Supportive Care and Others.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  75. MURRAY DC, Oechsli M, Pinkston C, Kkloecker GH, et al
    P2.31: Understanding Factors Influencing Self-Referral of Patients From Resource-Limited Institutions Seeking Lung Cancer Care: Track: Supportive Care and Others.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  76. AN X, Dong W, Sun Z
    P2.27: Blood Supplement Research of the Percutaneous Inoculated Canine Transmissible Venereal Tumor Lung Cancer Model: Track: Supportive Care and Others.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  77. ARAUZ E, Moreno-Rios J, Llerena JP, Sowley D T, et al
    P2.26: Reference to Palliative Care in Patients With Advanced Lung Cancer Treated With Systemic Therapy. Ion, Panama: Track: Supportive Care and Others.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  78. VERGARA R, Pinzon O, Sowley D T, Martin C, et al
    P2.17: Incidence of Non-Small Cell Lung Cancer Biomarkers in Panama; Demographyc, Clinic and Histopathological Features: Track: Pathology.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  79. OROZCO KM, Trujillo LF, Sua LF
    P2.14: Lung Cancer as Second Primary Cancer in Two Patients in a Reference Hospital in Latin America: A Case Report: Track: Pathology.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  80. SOWLEY D T, Moreno-Rios J, Arauz E, Vergara R, et al
    P2.10: Clinical and Pathological Characteristics of ALK Positive Lung Cancer Patients. Instituto Oncologico Nacional - Panama: Track: Biology and Pathogenesis.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  81. ARGUELLO D, Swensen J, Ellis P, Kimbrough J, et al
    P2.08: Gene Fusions Detected in Non-Small Cell Lung Carcinoma (NSCLC) and Small Cell Lung Carcinoma (SCLC): Track: Biology and Pathogenesis.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  82. RECLUSA P, Giallombardo M, Castiglia M, Sorber L, et al
    P2.06: Exosomal miRNA Analysis in Non-Small Cell Lung Cancer: New Liquid Biomarker?: Track: Biology and Pathogenesis.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  83. GITLITZ B, Addario B, Sable-Hunt A, Novello S, et al
    P1.49 (also presented as PD1.05): The Genomics of Young Emergent Lung Cancer: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  84. GRIDELLI C, Chen T, Ko A, Ong TJ, et al
    P1.48: nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung Cancer: Outcomes in Elderly Patients With Squamous Histology: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  85. GEORGE B, Kelly K, Ko A, Soliman H, et al
    P1.46: Phase I Study of Nivolumab + Nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  86. AMENDOLA B, Wolf A, Coy S
    P1.43 (also presented as PD2.05): Radiosurgery, a New Paradigm in Metastatic Non-Small Cell Lung Cancer (NSCLC) to the Brain: An Update: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  87. LOPES G
    P1.41 (also presented as PD2.06): Bayesian Network Meta-Comparison of Maintenance Treatments for Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  88. GILANI S, Jegannathen A, Vanpittius G, Vengalil S, et al
    P1.37: First Line Treatment Outcome for EGFR Mutated Metastatic Non-Small Cell Lung Cancer-A Single Institution 5 Years Experience: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  89. AMENDOLA B, Amendola MA, Perez NC, Wu X, et al
    P1.35: The Role of Salvage SBRT in Recurrent Lung Cancer After Previous Radiotherapy: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  90. WEIS LN, Coelho JC, Marks P, Geib G, et al
    P1.36: Non-Small-Cell Lung Cancer and Brain Metastases in Brazil: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  91. AIX SP, Park K, Tan EH, O'Byrne K, et al
    P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  92. GRADICA F, Gradica F, Rexha V, Lisha L, et al
    P1.32: Primary Lung Cancer Presenting as Pneumothorax: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  93. FELIZARDO M, Matos CP, Furtado ST, Coelho JP, et al
    P1.26: A Case of Non Small Cell Lung Cancer EGFR Mutation EXON 18 Positive With Poor Response to Targeted Therapy: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  94. ARAUZ E, Lopez R, Cabreja A, Martin C, et al
    P1.25: Experience With Erlotinib and Gefitnib in Patients With EGFR Mutation Positive Advanced Lung Cancer: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  95. AYALA LEON SJ, Pino MA, Colas CG, Pereira MR, et al
    P1.23: Chemotherapy in Lung Cancer at National Institute of Oncology at Paraguay: A Retrospective Study, 8 Years of Experience: Track: Advanced NSCLC.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  96. FERNANDEZ L, Henao JF, Sua LF, Zuniga V, et al
    P1.19: Barriers to Deliver Personalized Medicine to Young Patients With Non-Small Cell Lung Cancer in Latin America: Track: Early Stage NSCLC (Stage I - III).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  97. RAEZ LE, Santos ES, Mourafetis J, Kim AY, et al
    P1.13 (also presented as PD2.01): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar: Track: Prevention, Early Detection, Epidemiology and Tobacco Control.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  98. RICHARDET E, Villavicencio R, Hernandez PA, Acosta L, et al
    P1.09: Delays in the Diagnosis and Treatment of Lung Cancer: Track: Prevention, Early Detection, Epidemiology and Tobacco Control.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  99. CORRALES-RODRIGUEZ L, Juarez M, Ramos-Esquivel A, Caballero M, et al
    P1.10: Follow-Up on Results of a Multidisciplinary Team in the Management of Non-Small Cell Lung Cancer in a Developing Country: Track: Prevention, Early Detection, Epidemiology and Tobacco Control.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  100. WERUTSKY G, Debiasi M, Sampaio FH, Nunes Filho PR, et al
    P1.08: Updated Analysis of Global Epidemiology of EGFR Mutation in Advanced Non-Small Cell Lung Cancer: Track: Prevention, Early Detection, Epidemiology and Tobacco Control.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  101. AMOS CI, Hung R, Bosse Y, Christiani DC, et al
    P1.04: Defining the Genetic Architecture of Lung Cancer Etiology: Track: Prevention, Early Detection, Epidemiology and Tobacco Control.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  102. MOLINA R, Marrades R, Reguart N, Agusti A, et al
    P1.03: Utility of a Combined Panel of Six Serum Tumor Markers for Lung Cancer: Track: Prevention, Early Detection, Epidemiology and Tobacco Control.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  103. AYALA LEON SJ, Pino MA, Colas CG, Pereira MR, et al
    P1.02: Lung Cancer - A Previously Years Survival Study. First Statistical Evidence at National Institute of Oncology in Paraguay: Track: Prevention, Early Detection, Epidemiology and Tobacco Control.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  104. AMENDOLA B, Wolf A, Coy S
    PD2.05 (also presented as P1.43): Radiosurgery, a New Paradigm in Metastatic Non-Small Cell Lung Cancer (NSCLC) to the Brain: An Update.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  105. LOPES G
    PD2.06 (also presented as P1.41): Bayesian Network Meta-Comparison of Maintenance Treatments for Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  106. RAEZ LE, Santos ES, Mourafetis J, Kim AY, et al
    PD2.01 (also presented as P1.13): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  107. GITLITZ B, Addario B, Sable-Hunt A, Novello S, et al
    PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  108. ARGUELLO D, Voss A, Gatalica Z, Bender R, et al
    O.04: Profiling of MET-Amplified Non-Small Cell Lung Cancer (NSCLC), Correlation to cMET Protein Expression/MET Exon 14 Skipping.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  109. AGUIAR P JR, De Mello R, Tadokoro H, Santoro I, et al
    O.03: Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  110. MACK PC, Banks KC, Zill OA, Mortimer SA, et al
    O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


    September 2016
  111. IGNATIUS OU SH, Govindan R, Eaton KD, Otterson GA, et al
    Brief Report: Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Sep 30. pii: S1556-0864(16)31119.
    PubMed     Text format     Abstract available


  112. LU S, Tan KS, Kadota K, Eguchi T, et al
    Spread Through Air Spaces (STAS) is an Independent Predictor of Recurrence and Lung Cancer Specific Death in Squamous Cell Carcinoma.
    J Thorac Oncol. 2016 Sep 28. pii: S1556-0864(16)31117.
    PubMed     Text format     Abstract available


  113. YU H, Batenchuk C, Badzio A, Boyle TA, et al
    PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Sep 14. pii: S1556-0864(16)30947.
    PubMed     Text format     Abstract available


  114. MASSION PP, Healey GF, Peek LJ, Fredericks L, et al
    Brief Report: Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-based Risk Models for Detection of Lung Cancer.
    J Thorac Oncol. 2016 Sep 8. pii: S1556-0864(16)30928.
    PubMed     Text format     Abstract available


  115. TORRES-DURAN M, Fernandez-Villar A, Barros-Dios JM, Ruano-Ravina A, et al
    Residential Radon: The Neglected Risk Factor in Lung Cancer Risk Scores.
    J Thorac Oncol. 2016;11:1384-6.
    PubMed     Text format     Abstract available


  116. SATTLER M, Salgia R
    MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer.
    J Thorac Oncol. 2016;11:1381-3.
    PubMed     Text format    


  117. ROTHSCHILD SI
    Lung Cancer in Pregnancy-A Forgotten Disease Entity.
    J Thorac Oncol. 2016;11:1376-8.
    PubMed     Text format    


    August 2016
  118. LANGER CJ, Obasaju C, Bunn P, Bonomi P, et al
    Incremental innovation and progress in advanced squamous cell lung cancer: current status and future impact of treatment.
    J Thorac Oncol. 2016 Aug 26. pii: S1556-0864(16)30905.
    PubMed     Text format     Abstract available


  119. WIESWEG M, Eberhardt WE, Reis H, Ting S, et al
    High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer.
    J Thorac Oncol. 2016 Aug 26. pii: S1556-0864(16)30904.
    PubMed     Text format     Abstract available


  120. ROSELL R, Neninger E, Nicolson M, Huber RM, et al
    Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2016 Aug 23. pii: S1556-0864(16)30898.
    PubMed     Text format     Abstract available


  121. ADACHI H, Sakamaki K, Nishii T, Yamamoto T, et al
    Lobe-specific lymph node dissection as a standard procedure in surgery for non-small-cell lung cancer: A propensity score matching study.
    J Thorac Oncol. 2016 Aug 20. pii: S1556-0864(16)30847.
    PubMed     Text format     Abstract available


  122. LIN JJ, Kennedy E, Sequist LV, Brastianos PK, et al
    Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2016 Aug 17. pii: S1556-0864(16)30845.
    PubMed     Text format     Abstract available


  123. TAIOLI E, Flores R
    Brief Report: Appropriateness of Surgical Approach in Black Lung Cancer Patients - 15 Years Later, Little has Changed.
    J Thorac Oncol. 2016 Aug 17. pii: S1556-0864(16)30834.
    PubMed     Text format     Abstract available


  124. PUJOL JL, De Pas T, Rittmeyer A, Vallieres E, et al
    Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study.
    J Thorac Oncol. 2016 Aug 17. pii: S1556-0864(16)30835.
    PubMed     Text format     Abstract available


  125. CARGNIN S, Canonico PL, Genazzani AA, Terrazzino S, et al
    Quantitative analysis of circulating cell-free DNA for correlation with lung cancer survival: a systematic review and meta-analysis.
    J Thorac Oncol. 2016 Aug 16. pii: S1556-0864(16)30711.
    PubMed     Text format     Abstract available


  126. ZHANG Z, Shiratsuchi H, Palanisamy N, Nagrath S, et al
    Expanded CTCs from a Patient with ALK Positive Lung Cancer Present EML4-ALK Rearrangement along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.
    J Thorac Oncol. 2016 Aug 6. pii: S1556-0864(16)30706.
    PubMed     Text format     Abstract available


  127. ITO K, Hataji O, Kobayashi H, Fujiwara A, et al
    Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small-Cell Lung Cancer - A Multicenter Retrospective Study.
    J Thorac Oncol. 2016 Aug 4. pii: S1556-0864(16)30701.
    PubMed     Text format     Abstract available


  128. XU W, Jia G, Davie JR, Murphy L, et al
    A 10-gene Yin Yang Expression Ratio Signature for Stage IA and IB non-small cell lung cancer.
    J Thorac Oncol. 2016 Aug 4. pii: S1556-0864(16)30702.
    PubMed     Text format     Abstract available


  129. KIM Y, Jin D, Lee BB, Cho EY, et al
    Overexpression of beta-catenin and cyclin D1 is associated with poor overall survival in stage IA-IIA squamous cell lung cancer irrespective of adjuvant chemotherapy.
    J Thorac Oncol. 2016 Aug 3. pii: S1556-0864(16)30700.
    PubMed     Text format     Abstract available


  130. CASTELLANO JJ, Navarro A, Vinolas N, Marrades RM, et al
    LincRNA-p21 impacts prognosis in resected non-small-cell lung cancer patients through angiogenesis regulation.
    J Thorac Oncol. 2016 Aug 2. pii: S1556-0864(16)30692.
    PubMed     Text format     Abstract available


  131. ALTORKI NK, Kamel MK, Narula N, Ghaly G, et al
    Anatomical segmentectomy and wedge resections are associated with comparable outcomes for small cT1N0 non-small cell lung cancer.
    J Thorac Oncol. 2016 Aug 2. pii: S1556-0864(16)30695.
    PubMed     Text format     Abstract available


  132. SHUKUYA T, Mori K, Amann JM, Bertino EM, et al
    Relationship between overall survival and response or progression-free survival in advanced non-small cell lung cancer patients treated with anti PD-1/PD-L1 antibodies.
    J Thorac Oncol. 2016 Aug 2. pii: S1556-0864(16)30694.
    PubMed     Text format     Abstract available


  133. KOCHER F, Ng C, Augustin F
    On the Article "Nodal Upstaging Is More Common with Thoracotomy Than with VATS during Lobectomy for Early-Stage Lung Cancer: An Analysis from the National Cancer Data Base" by Medbery et al.
    J Thorac Oncol. 2016;11:e103-4.
    PubMed     Text format    


  134. RAMI-PORTA R, Asamura H, Brierley J, Goldstraw P, et al
    Staging, Tumor Profile, and Prognostic Groups in Lung Cancer or the New Tower of Babel.
    J Thorac Oncol. 2016;11:1201-3.
    PubMed     Text format    


  135. MOLNAR TF, Kollar D
    Glasgow Prognostic Score: Another Global Positioning System to Assess Patients with Lung Cancer?
    J Thorac Oncol. 2016;11:1194-6.
    PubMed     Text format    


    July 2016
  136. IBRAHIM M, Parry S, Wilkinson D, Bilbe N, et al
    ALK Immunohistochemistry in Non-Small Cell Lung Carcinoma (NSCLC): Discordant Staining Can Impact Patient Treatment Regimen.
    J Thorac Oncol. 2016 Jul 25. pii: S1556-0864(16)30630.
    PubMed     Text format     Abstract available


  137. NOVELLO S, Scagliotti G, de Castro G Jr, Kiyik M, et al
    Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Jul 24. pii: S1556-0864(16)30631.
    PubMed     Text format     Abstract available


  138. LI YS, Jiang BY, Yang JJ, Tu HY, et al
    Leptomeningeal metastases in non-small cell lung cancer patients with EGFR mutations.
    J Thorac Oncol. 2016 Jul 22. pii: S1556-0864(16)30626.
    PubMed     Text format     Abstract available


  139. DETTERBECK F, Chansky K, Groome P, Bolejack V, et al
    The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of Non-Small Cell Lung Cancer in the Forthcoming (8th) Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2016 Jul 20. pii: S1556-0864(16)30616.
    PubMed     Text format     Abstract available


  140. CONDUIT C, Hardikar A, Prasad R, Nott L, et al
    Occam's razor and Hickam's dictum: a rare case of synchronous solid and hematological malignancies and transformed EGFR-mutated non-small cell lung cancer.
    J Thorac Oncol. 2016 Jul 19. pii: S1556-0864(16)30610.
    PubMed     Text format     Abstract available


  141. MAKINSON A, Le Moing V, Reynes J, Ferry T, et al
    Lung cancer screening with Chest Computed Tomography in People Living with HIV. A review by the multidisciplinary CANCERVIH Working Group.
    J Thorac Oncol. 2016 Jul 19. pii: S1556-0864(16)30609.
    PubMed     Text format     Abstract available


  142. KIM H, Chan Ahn Y, Pyo H, Oh D, et al
    Do new pN sub-classifications, proposed by IASLC's lung cancer staging project, agree with ypN categories following tri-modality therapy for initial N2 disease?
    J Thorac Oncol. 2016 Jul 13. pii: S1556-0864(16)30603.
    PubMed     Text format     Abstract available


  143. WAQAR SN, Bonomi PD, Govindan R, Hirsch FR, et al
    Clinician Perspectives on Current Issues in Lung Cancer Drug Development.
    J Thorac Oncol. 2016 Jul 8. pii: S1556-0864(16)30459.
    PubMed     Text format     Abstract available


  144. BILLIET C, Peeters S, Decaluwe H, Vansteenkiste J, et al
    Outcome after post-operative radiotherapy (PORT) in ypN2 or R1/R2 versus no PORT in ypN0 stage III-N2 non-small cell lung cancer after induction chemotherapy and resection.
    J Thorac Oncol. 2016 Jul 5. pii: S1556-0864(16)30593.
    PubMed     Text format     Abstract available


  145. LI Y, Li J, Zhang R
    Authors' Response to Letter "Reliability Assurance of EML4-ALK Rearrangement Detection in Non-Small Cell Lung Cancer: A Methodological and Statistical Issue".
    J Thorac Oncol. 2016;11:e93-4.
    PubMed     Text format    


  146. SABOUR S
    Reliability Assurance of EML4-ALK Rearrangement Detection in Non-Small Cell Lung Cancer: A Methodological and Statistical Issue.
    J Thorac Oncol. 2016;11:e92-3.
    PubMed     Text format    


    June 2016
  147. BILLIET C, De Ruysscher D, Peeters S, Decaluwe H, et al
    Patterns of loco-regional relapses in contemporarily staged stage III-N2 non-small cell lung cancer patients treated with induction chemotherapy and resection: Implications for postoperative radiotherapy target volumes.
    J Thorac Oncol. 2016 Jun 30. pii: S1556-0864(16)30589.
    PubMed     Text format     Abstract available


  148. CROSBIE PA, Shah R, Krysiak P, Zhou C, et al
    A brief report: Circulating tumour cells detected in the tumour-draining pulmonary vein are associated with disease recurrence after surgical resection of non-small cell lung cancer.
    J Thorac Oncol. 2016 Jun 30. pii: S1556-0864(16)30586.
    PubMed     Text format     Abstract available


  149. RAZ DJ, Wu GX, Consunji M, Nelson R, et al
    Perceptions and utilization of lung cancer screening among primary care physicians.
    J Thorac Oncol. 2016 Jun 23. pii: S1556-0864(16)30527.
    PubMed     Text format     Abstract available


  150. SANDFELD-PAULSEN B, Jakobsen KR, Baek R, Folkersen BH, et al
    Exosomal Proteins as a Diagnostic Biomarkers in Lung Cancer.
    J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30517.
    PubMed     Text format     Abstract available


  151. SCHROCK AB, Frampton GM, Suh J, Chalmers ZR, et al
    Characterization of 298 lung cancer patients harboring MET exon 14 skipping (METex14) alterations.
    J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30521.
    PubMed     Text format     Abstract available


  152. HEIST RS, Sequist LV, Borger D, Gainor JF, et al
    Acquired Resistance to Crizotinib in Non-small Cell Lung Cancer with MET exon 14 skipping.
    J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30530.
    PubMed     Text format     Abstract available


  153. VERNON J, Andruszkiewicz N, Schneider L, Schieman C, et al
    Comprehensive clinical staging for resectable lung cancer: Clinico-pathological correlations and the role of brain MRI.
    J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30520.
    PubMed     Text format     Abstract available


  154. KHALIFA J, Amini A, Popat S, Gaspar LE, et al
    Brain metastases from non-small cell lung cancer: radiation therapy in the era of targeted therapies.
    J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30519.
    PubMed     Text format     Abstract available


  155. MATTER-WALSTRA K, Schwenkglenks M, Aebi S, Dedes K, et al
    A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing.
    J Thorac Oncol. 2016 Jun 13. pii: S1556-0864(16)30507.
    PubMed     Text format     Abstract available


  156. SOCINSKI MA, Obasaju C, Gandara D, Hirsch FR, et al
    Clinicopathologic features of advanced squamous non-small cell lung cancer.
    J Thorac Oncol. 2016 Jun 10. pii: S1556-0864(16)30499.
    PubMed     Text format     Abstract available


  157. ARRIOLA E, Wheater M, Galea I, Cross N, et al
    Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer.
    J Thorac Oncol. 2016 Jun 10. pii: S1556-0864(16)30503.
    PubMed     Text format     Abstract available


  158. WILLIAMS CD, Salama JK, Moghanaki D, Karas TZ, et al
    Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer.
    J Thorac Oncol. 2016 Jun 10. pii: S1556-0864(16)30505.
    PubMed     Text format     Abstract available


  159. TAN DS, Araujo A, Zhang J, Signorovitch J, et al
    Comparative Efficacy of Ceritinib and Crizotinib as Initial Anaplastic Lymphoma Kinase-targeted Therapies in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: an Adjusted Comparison to External Controls.
    J Thorac Oncol. 2016 Jun 8. pii: S1556-0864(16)30504.
    PubMed     Text format     Abstract available


  160. FACCHINETTI F, Marabelle A, Rossi G, Soria JC, et al
    Moving immune checkpoint blockade in thoracic tumors beyond non-small cell lung cancer.
    J Thorac Oncol. 2016 Jun 8. pii: S1556-0864(16)30502.
    PubMed     Text format     Abstract available


  161. MORGENSZTERN D, Du L, Waqar SN, Patel A, et al
    Adjuvant Chemotherapy for Patients with T2N0M0 Non-small-cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2016 Jun 8. pii: S1556-0864(16)30497.
    PubMed     Text format     Abstract available


  162. SHINTANI Y, Fujiwara A, Kimura T, Kawamura T, et al
    IL-6 secreted from cancer associated fibroblasts mediates chemoresistance in non-small-cell lung cancer by increasing epithelial-mesenchymal transition signaling.
    J Thorac Oncol. 2016 Jun 8. pii: S1556-0864(16)30500.
    PubMed     Text format     Abstract available


  163. CHENG TD, Cramb SM, Baade PD, Youlden DR, et al
    The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics.
    J Thorac Oncol. 2016 Jun 7. pii: S1556-0864(16)30496.
    PubMed     Text format     Abstract available


  164. GIRON J, Lacout A, Marcy PY
    Dealing with Lung Cancer TNM Classification.
    J Thorac Oncol. 2016;11:e77-8.
    PubMed     Text format    


  165. REDIG AJ, Janne PA
    No Target Left Behind: Improving Therapeutic Options for ERBB2-Mutant Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016;11:784-6.
    PubMed     Text format    


    May 2016
  166. WANG BY, Huang JY, Ko JL, Chou CT, et al
    Thoracoscopic Lobectomy Produces Similar Long Term Survival Compared With Open Lobectomy in Cases of Non-Small Cell Lung Carcinoma: A Propensity-Matched Analysis Using a Population-Based Cancer Registry.
    J Thorac Oncol. 2016 May 30. pii: S1556-0864(16)30486.
    PubMed     Text format     Abstract available


  167. SUDA K, Murakami I, Yu H, Ellison K, et al
    Heterogeneity of EGFR aberrations and correlation with histological morphologies: analyses of therapy naive isogenic lung cancer lesions with EGFR mutation.
    J Thorac Oncol. 2016 May 30. pii: S1556-0864(16)30492.
    PubMed     Text format     Abstract available


  168. BERSANELLI M, Minari R, Bordi P, Gnetti L, et al
    L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated non-small cell lung cancer.
    J Thorac Oncol. 2016 May 30. pii: S1556-0864(16)30494.
    PubMed     Text format     Abstract available


  169. LIU SY, Gou LY, Li AN, Lou NN, et al
    The unique characteristics of MET exon 14 mutation in Chinese non-small cell lung cancer patients.
    J Thorac Oncol. 2016 May 30. pii: S1556-0864(16)30490.
    PubMed     Text format     Abstract available


  170. HISHIDA T, Miyaoka E, Yokoi K, Tsuboi M, et al
    Lobe-specific nodal dissection for clinical stage I-II non-small cell lung cancer: Japanese multi-institutional retrospective study using a propensity score analysis.
    J Thorac Oncol. 2016 May 29. pii: S1556-0864(16)30485.
    PubMed     Text format     Abstract available


  171. JAIN A, Luo J, Chen Y, Henderson M, et al
    Current patterns of care for patients with Extensive Stage Small Cell Lung Cancer: survey of US radiation oncologists on their recommendations regarding prophylactic cranial irradiation.
    J Thorac Oncol. 2016 May 26. pii: S1556-0864(16)30465.
    PubMed     Text format     Abstract available


  172. SHAVERDIAN N, Veruttipong D, Wang J, Kupelian P, et al
    Pretreatment anemia portends poor survival and non-local disease progression in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy.
    J Thorac Oncol. 2016 May 24. pii: S1556-0864(16)30462.
    PubMed     Text format     Abstract available


  173. YOTSUKURA M, Ohtsuka T, Kaseda K, Kamiyama I, et al
    Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 May 24. pii: S1556-0864(16)30461.
    PubMed     Text format     Abstract available


  174. TAN DS, Yom SS, Tsao MS, Pass HI, et al
    The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation positive non-small cell lung cancer: status in 2016.
    J Thorac Oncol. 2016 May 20. pii: S1556-0864(16)30458.
    PubMed     Text format     Abstract available


  175. LEVENTAKOS K, Kipp BR, Rumilla KM, Winters JL, et al
    Brief Report: S768I mutation in EGFR in patients with lung cancer.
    J Thorac Oncol. 2016 May 19. pii: S1556-0864(16)30457.
    PubMed     Text format     Abstract available


  176. HALPENNY DF, Cunningham JD, Long NM, Sosa RE, et al
    Patients With A Previous History Of Malignancy Undergoing Lung Cancer Screening: Clinical Characteristics And Radiologic Findings.
    J Thorac Oncol. 2016 May 17. pii: S1556-0864(16)30456.
    PubMed     Text format     Abstract available


  177. DING X, Hui Z, Dai H, Fan C, et al
    A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-small Cell Lung Cancer.
    J Thorac Oncol. 2016 May 17. pii: S1556-0864(16)30453.
    PubMed     Text format     Abstract available


  178. WARD MC, Oh SC, Pham Y, Woody NM, et al
    Isolated Nodal Failure after Stereotactic Body Radiotherapy for Lung Cancer: The Role for Salvage Mediastinal Radiotherapy.
    J Thorac Oncol. 2016 May 17. pii: S1556-0864(16)30452.
    PubMed     Text format     Abstract available


  179. KOINIS F, Vetsika EK, Aggouraki D, Skalidaki E, et al
    Effect of first-line treatment on myeloid-derived suppressor cells' subpopulations in the peripheral blood of non-small cell lung cancer patients.
    J Thorac Oncol. 2016 May 10. pii: S1556-0864(16)30408.
    PubMed     Text format     Abstract available


  180. NAKASHIMA K, Horita N, Nagai K, Manabe S, et al
    Progression-free survival, response rate, and disease control rate as predictors of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy advanced/locally-advanced/recurrent non-small cell lung carcinoma: A
    J Thorac Oncol. 2016 May 10. pii: S1556-0864(16)30407.
    PubMed     Text format     Abstract available


  181. IWAMA E, Okamoto I, Yabuuchi H, Takayama K, et al
    Characteristics of smoking lung cancer patients with emphysematous bullae.
    J Thorac Oncol. 2016 May 6. pii: S1556-0864(16)30405.
    PubMed     Text format     Abstract available


  182. HA D, Mazzone PJ, Ries AL, Malhotra A, et al
    The Utility of Exercise Testing in Patients with Lung Cancer.
    J Thorac Oncol. 2016 May 5. pii: S1556-0864(16)30402.
    PubMed     Text format     Abstract available


  183. PURI V, Robinson CG
    In Response to Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy.
    J Thorac Oncol. 2016;11:e65-6.
    PubMed     Text format    


  184. POULLIS M
    Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy.
    J Thorac Oncol. 2016;11:e64-5.
    PubMed     Text format    


    April 2016
  185. VIOLA P, Maurya M, Croud J, Gazdova J, et al
    A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer.
    J Thorac Oncol. 2016 Apr 28. pii: S1556-0864(16)30082.
    PubMed     Text format     Abstract available


  186. LEVIN PA, Brekken RA, Byers LA, Heymach JV, et al
    Axl receptor axis: a new therapeutic target in lung cancer.
    J Thorac Oncol. 2016 Apr 26. pii: S1556-0864(16)30341.
    PubMed     Text format     Abstract available


  187. YU H, Boyle TA, Zhou C, Rimm D, et al
    PD-L1 Expression in Lung Cancer.
    J Thorac Oncol. 2016 Apr 23. pii: S1556-0864(16)30340.
    PubMed     Text format    


  188. ZENKE Y, Umemura S, Motegi A, Furukawa K, et al
    Acute and progressive tracheal stenosis after proton beam therapy with concurrent chemotherapy for non-small cell lung cancer.
    J Thorac Oncol. 2016 Apr 21. pii: S1556-0864(16)30337.
    PubMed     Text format    


  189. TRAVIS WD, Asamura H, Bankier AA, Beasley MB, et al
    The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2016 Apr 20. pii: S1556-0864(16)30335.
    PubMed     Text format     Abstract available


  190. SHAIKH T, Churilla TM, Murphy CT, Zaorsky NG, et al
    Absence of pathological proof of cancer associated with improved outcomes in early stage lung cancer.
    J Thorac Oncol. 2016 Apr 19. pii: S1556-0864(16)30105.
    PubMed     Text format     Abstract available


  191. ARNOLD BN, Thomas DC, Rosen JE, Salazar MC, et al
    Lung cancer in the very young: treatment and survival in the National Cancer DataBase.
    J Thorac Oncol. 2016 Apr 18. pii: S1556-0864(16)30094.
    PubMed     Text format     Abstract available


  192. SUN JM, Zhou W, Choi YL, Choi SJ, et al
    Prognostic Significance of Programmed Cell Death Ligand 1 in Patients With Non-Small-Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
    J Thorac Oncol. 2016 Apr 18. pii: S1556-0864(16)30095.
    PubMed     Text format     Abstract available


  193. GELSOMINO F, Ambrosini V, Melotti B, Sperandi F, et al
    Pitfalls in oncology: osteoblastic response mimicking bone progression during ceritinib treatment in ALK-rearranged non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2016 Apr 11. pii: S1556-0864(16)30084.
    PubMed     Text format    


  194. DZIADZIUSZKO R, Le AT, Wrona A, Jassem J, et al
    An activating KIT mutation induces crizotinib resistance in ROS1 positive lung cancer.
    J Thorac Oncol. 2016 Apr 8. pii: S1556-0864(16)30083.
    PubMed     Text format     Abstract available


  195. DE MARINIS F, Bria E, Ciardiello F, Crino L, et al
    International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Anti-angiogenetic Drugs for Non-Small-Cell Lung Cancer: Realities and Hopes.
    J Thorac Oncol. 2016 Apr 5. pii: S1556-0864(16)30072.
    PubMed     Text format     Abstract available


  196. ISAKA M, Kondo H, Maniwa T, Takahashi S, et al
    Boundary between N1 and N2 lymph node descriptors in the subcarinal zone in lower lobe lung cancer: A brief report.
    J Thorac Oncol. 2016 Apr 4. pii: S1556-0864(16)30071.
    PubMed     Text format     Abstract available


  197. SHEN C, Che G
    A Different Method in Diagnosis of Multiple Primary Lung Cancer.
    J Thorac Oncol. 2016;11:e53-4.
    PubMed     Text format    


  198. HALL SR, Wang L, Marti TM, Peng RW, et al
    98O: Characterization of tumor infiltrating lymphocytes in resectable early stage non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  199. SHAIKH T, Churilla T, Murphy C, Zaorsky NG, et al
    97O: Overtreatment of patients with clinically diagnosed early stage lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  200. PULIGUNDLA KC, Gundeti S, Maddali LS, Stalin B, et al
    96P: Small cell lung cancer: Prognostic factors and outcome at a tertiary care centre in South India.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  201. AKSARIN AA, Ter-Ovanesov MD, Parsadanyan AM, Kopeyka SM, et al
    95P: The role of surgery in combination treatment of patients with small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  202. BENE GD, Prelaj A, Berrios JR, Filippis LD, et al
    94P: First-line treatment with cisplatin plus etoposide for small cell lung cancer and large cell neuroendocrine carcinoma: Our center experience.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  203. HIGGINS E, Edwards G, Tanguay J, Button M, et al
    93P: Chemoradiotherapy with radical intent for small cell lung cancer (SCLC): A 5 year retrospective review.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  204. ROTHSCHILD SI, Hagmann R, Zippelius A
    92P: Validation of prognostic scores in small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  205. TENDLER S, Lewensohn R, Viktorsson K, de Petris L, et al
    91P: Validation of the 7th and upcoming 8th TNM staging system in small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  206. KIM YS, Yoon SH, Son BS, Kim DH, et al
    87P: Qualitative and quantitative interpretation of F-18 FDG PET/CT to differentiate metastatic mediastinal lymph node in non-small cell lung carcinoma patients with benign mediastinal lymph node hyperplasia.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  207. LEVENTAKOS K, Mansfield AS, Blackmon S, Cassivi S, et al
    88P: Use of brain imaging in the management of patients with lymph node negative multifocal lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  208. TSAKIRIDIS T, Villani L, Marcinko K, Pond G, et al
    84P Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  209. CHAO TT, Chen CH, Peng ZA, Wang CY, et al
    82P Synergistic antitumor activity of afatinib and nintedanib through PP2A reactivation in non-small-cell lung cancer cells.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  210. BONANNO L, Calabrese F, De Paoli A, Pasello G, et al
    77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  211. KARACHALIOU N, Chaib I, Pilotto S, Codony J, et al
    76P An innovative co-targeting of signal transducer and activator of transcription 3 (STAT3) and Src-YAP pathways in EGFR mutant non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  212. RAMA AR, Hernandez R, Jimenez J, Leiva MD, et al
    73P Generation of miR-21 sponges in lung cancer treatment.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  213. ROLFO C, Chacartegui J, Giallombardo M, Alessandro R, et al
    71P Exosomes isolated in plasma of non-small cell lung cancer patients contain microRNA related to the EGFR pathway: Proof of concept.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  214. O'BYRNE K, Ryan SL, Heavey S, Umezawa K, et al
    68P Inflammatory meditated mechanisms of cisplatin resistance in non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  215. TAKEUCHI M, Takasaki M, Miwa N, Tanaka Y, et al
    69P Effect of cigarette smoke exposure on anti-cancer activity of alveolar macrophage to Lewis lung carcinoma in mice.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  216. O'BYRNE K, Barr MP, Urquhart A, Ryan SL, et al
    67P Investigation of the interaction between non-small cell lung cancer cells and immortalised normal bronchial epithelial cells.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  217. BATY F, Jorger M, Frueh M, Brutsche MH, et al
    61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  218. HOU LL, Gu F, Zhou C
    53P Transcutaneous electrical acupoint stimulation ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  219. VOTRUBA J, Bruha T, Setnicka V, St'ovickova L, et al
    54P Correlation of Raman and NIR spectroscopy for diagnosis of peripheral lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  220. KUMAR V, Bhatt PC, Anwar F
    55P Development of a nanoformulation containing ganoderic acid for the prevention and treatment of the benzo[a]pyrene induced lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  221. GOYAL S, Bhadu I, Kapoor A, Raj NR, et al
    52P Chromosomal aberrations in peripheral blood lymphocytes of lung cancer patients: A possible tool for early diagnosis.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  222. LUMACHI F, Del Conte A, Sulfaro S, Chiara GB, et al
    49P Accuracy of pleural fluid cytology in patients with malignant pleural effusion from non-small-cell lung cancer, pulmonary metastases and pleural mesothelioma. A case-control study.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  223. ZHENG R, Fu Y, Xiang Q, Shi Y, et al
    46P The Huaxi Emotional-Distress Index: An instrument for screening distress in Chinese inpatients with lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  224. KOC Z, Cinarli T, Saglam Z, Celebi P, et al
    48P Determination of the association between continuous anger, anger expression and hope-hopelessness levels in patients with lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  225. GU F, Hou LL
    47P Self-reported depression among patients with non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  226. SYRIGOS K, Somarakis A, Triggidou R, Kainis I, et al
    45P Economic evaluation of two therapeutic approaches in non small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  227. KOC Z, Cinarli T, Saglam Z, Celebi P, et al
    44P Determination of care dependency in patients diagnosed with lung cancer and care burden in these patients' relatives.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  228. KAUR S, Mehta D, Kumar A, Kumar M, et al
    43P Health care utilization and burden of lung cancer over the last decade: A nationwide analysis.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  229. FAEHLING M, Schwenk B, Eckert R, Leschke M, et al
    38P Overall survival in non-smokers and quitters compared to smokers who develop lung cancer: Case-control data from routine clinical practice.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  230. SHA A
    37P Domestic cooking fuel as a risk factor for lung cancer in women: A case control study.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  231. ROTTENBERG Y, Uziely B, de Boer AG
    35P Unemployment risk among lung cancer survivors: A population based study.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  232. ABDELFATTAH SH, Wakeel HM, Elghamry WR, Ezzeldin MM, et al
    34P A retrospective analysis of the epidemiological and prognostic factors of non small cell lung cancer in an Egyptian tertiary referral center.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  233. LINARES I, Exposito J, Arrebola JP, Sanchez-Cantalejo J, et al
    33P Prognostic factors associated with lung cancer survival. A population-based study in the South of Spain.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  234. POWROZEK T, Krawczyk P, Kowalski D, Kuznar-Kaminska B, et al
    30PD Novel plasma circulating microRNA signature for early detection of non-small cell lung cancer in liquid biopsy.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  235. SYRIGOS K, Raptakis T, Koumarianou A, Grapsa D, et al
    29P Human papillomavirus and non small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  236. VLAJNIC T, Brady L, Casey O, Gately K, et al
    26P Characteristics of circulating tumor cells (CTCs) in patients with lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  237. ALMANOVA AS
    27P The impact of hypolipidemic drugs on course and prognosis of lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  238. MARTI TM, Dorn P, Tieche CC, Peng RW, et al
    23P Prolonged pemetrexed pretreatment increases efficiency of ionizing radiation combination therapy and correlates with the persistence of treatment-induced DNA damage in lung cancer cells.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  239. O'BYRNE K, Adams M, Burgess J, Richard D, et al
    24P CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  240. MARTI TM, Tieche CC, Peng RW, Dorn P, et al
    22P Increased schedule-dependent efficiency of pemetrexed-cisplatin combination therapy eliminates resistant lung cancer stem-like cells associated with EMT.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  241. LIANG S, Marti TM, Dorn P, Froment L, et al
    18P Epithelial-to-mesenchymal transition (EMT) is required for resistance to anti-folate chemotherapy in lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  242. MARRUGAL A, Marquez LO, Quintanal A, Molina-Pinelo S, et al
    19P Comparative effectiveness analysis of HSP90 inhibitors in non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  243. O'BYRNE K, Burgess J, Bolderson E, Adams M, et al
    16P The overexpression of SASH1 stimulates cell death in lung cancer cells.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  244. BREIVA D, Tracums I, Jaunalksne I, Krievins D, et al
    14P Tumor microcirculation based biomarker discovery strategy for non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  245. SHI M
    6P Expression of PD-L1 in lung cancer cells regulates Treg cell differentiation.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  246. NIKOLAIENKO T, Shelest D, Garmanchuk L, Dzhus O, et al
    7P Proangiogenic effect of peritoneal macrophages from animals with Lewis lung carcinoma.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  247. GATALICA Z, Feldman R, Russell K, Voss A, et al
    1PD Differences in expression of predictive biomarkers between primary and metastatic non-small cell lung cancer tumors.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  248. GRIDELLI C, Ko A, O'Brien M, Ong TJ, et al
    216PD: nab-Paclitaxel + carboplatin (nab-P/C) in advanced non-small cell lung cancer (NSCLC): outcomes in elderly patients (pts) with squamous (SCC) histology.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  249. PAZ-ARES L, Socinski MA, Shahidi J, Hozak RR, et al
    1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-lin
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  250. JENKINS S, Yang J, Ramalingam S, Yu K, et al
    134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  251. LU HH, Chen BC, Chen HW, Ho CC, et al
    205P: Visualizing ZO-1-mediated coupled migration between cancer and stromal cells in lung cancer metastasis via a 5-dimensional cell imaging system.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  252. SERDAREVIC M, Kukulj S, Nikolic I, Taradi I, et al
    203P: Could neutrophil-to-lymphocyte ratio be predictor of brain metastases in non small cell lung cancer?
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  253. STALIN B, Gundeti S, Kumar A, Maddali LS, et al
    201P: Pattern of metastases and their impact on outcomes in stage IV non small cell lung cancer - an institutional experience from South India.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  254. GUCKENBERGER M, Lang S, Hoyer M, Fode MM, et al
    198PD: Nomogram for predicting overall survival after stereotactic body radiotherapy for pulmonary metastases: Development and external validation.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  255. BURNS K, Harle AS, Blackhall F, Fenemore J, et al
    196TiP: PREM-LC: Development and pilot testing of a patient reported experience measure in lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  256. PARK K, Han JY, Kim DW, Bazhenova LA, et al
    190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  257. KHALAF M, Attia AM
    188P: Palliative hypofractionated radiotherapy in south Egyptian patients with stage III and IV non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  258. MOL MD, Visser S, Oudsten BL, Van Walree NC, et al
    187P: Patient's feelings about side-effects are predictive for (Health Related) Quality of Life in patients with advanced stage lung cancer treated with chemotherapy.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  259. GIRARD N, Corral J, Cortinovis D, Heigener D, et al
    183P: Second-line treatment selection in patients with non-small cell lung cancer of adenocarcinoma histology: A European survey.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  260. SANTOS ES, Castillero LD
    186P: Antiangiogenic therapy using bevacizumab in patients older than 75 years old with stage IV non-squamous non small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  261. SAIGUSA M, Sakurai S, Akamatsu T, Yamamoto A, et al
    184P: The efficacy and safety of amrubicin in non-small-cell lung cancer patients beyond third-line therapy.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  262. DUDNIK E, Moskovitz M, Wollner M, Zer A, et al
    181P: Anti-PD-1 antibodies in non-small cell lung cancer (NSCLC): The real-life setting experience.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  263. MIELGO X, Toro P, Ruiz-Gimenez L, Olier C, et al
    179P: Nivolumab monotherapy in patients with previously treated advanced non-small cell lung cancer (NSCLC) in routine clinical practice in a Spanish center.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  264. PEREZ JM, Gonzalez AF, Simon IS, Cervera A, et al
    180P: Immunotherapy as an effective therapy approach for advanced non-small cell lung cancer (NSCLC): A single institution experience in the context of clinical trials and expanded access use.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  265. KIM E, Usari T, Polli A, Lewis I, et al
    177P: Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  266. ZER A, Hershko-Klement A, Hwang D, Korpanty G, et al
    176P: ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  267. WILNER K, Usari T, Polli A, Kim E, et al
    174P: Comparison of cardiovascular effects of crizotinib and chemotherapy in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  268. RAMASWAMY A, Patil VM, Noronha V, Joshi A, et al
    175P: ALK positive lung cancer: Clinical profile and outcomes in a developing country.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  269. CHENG CC, Su JL
    173P: Vascular endothelial growth factor-C promotes EGFR-TKIs resistance and cancer stemness via SLUG of non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  270. NEUMAIR P, Joos L, Warschkow R, Ess S, et al
    169P: Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  271. PASELLO G, Polo V, Frega S, Lorenzi M, et al
    166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  272. CADRANEL J, Brambilla E, Morere JF, Rondeau V, et al
    168P: Real life practice of gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC) depending on epidermal growth factor receptor (EGFR) mutation status: Results from the prospective EPIDAURE study.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  273. ITOTANI R, Marumo S, Fukui M
    164P: A review of prognostic factors for patients with epidermal growth factor receptor mutation positive advanced non small cell lung cancer (EGFR+NSCLC).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  274. RENHUA G, Yue S, Shidai J, Jing F, et al
    165P: Long noncoding RNA LUCAT1 is associated with poor prognosis in human non-small cell lung cancer and affects cell proliferation via regulating p21 and p57 expression.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  275. POPOVSKA S, Chilingirova N, Dineva T, Kamburova Z, et al
    163P: Prevalence of epidermal growth factor receptor (EGFR) gene mutations in non small cell lung cancer (NSCLC) in Bulgarian population.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  276. ISMAIL M, Bastawisy AE, Gaafar R, Bahnassy A, et al
    162P: Molecular markers in advanced non small cell lung cancer patients receiving gemcitabine & cisplatin.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  277. COLOMA CS, Nino OM, Codina JG, Perez CE, et al
    159P: Early radiological response (ERR) as predictor of overall survival in non small cell lung cancer (NSCLC) patients with EGFR mutations.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  278. MOL MD, Visser S, Van Walree NC, Belderbos H, et al
    160P: Depressive symptoms, performance score, and personality traits as predictors of (health related) quality of life in patients with advanced stage lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  279. ESSINK A, Korse T, van den Heuvel M
    157P: Serum tumor markers and the response to immunotherapy in advanced non-small cell lung carcinoma.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  280. GAO HF, Wu YL, Yang JJ, Zhang XC, et al
    154P: Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  281. DO SK, Lee SY, Choi JE, Hong MJ, et al
    155P: PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  282. ROZENBLUM AB, Ilouze M, Dudnik E, Flex D, et al
    152P: The clinical utility of next-generation sequencing in lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  283. ARRIOLA E, Paredes A, Gomez RG, Diz P, et al
    147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  284. GUSTIN P, Tremolieres P, Peyraga G, Hureaux J, et al
    146P: The potential role for consolidative radiotherapy in oligometastatic non small cell lung cancer through the prism of pattern of failure analysis.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  285. MARIN S, Garde J, Coloma CS, Juan O, et al
    144P: Oligometastatic non-small-cell lung cancer (NSCLC) and unresectable primary tumor: Updated retrospective analysis of safety and efficacy of the radical treatment for the primary tumor and the metastases.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  286. COLOMA CS, Perez CE, Nino OM, Sanoyan DA, et al
    145P: Perspectives in oligometastatic brain lesions in non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  287. ZHANG J, Song Y, Zhou ZY, Zhang C, et al
    142PD: The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  288. FELIP E, Crino L, Kim DW, Spigel DR, et al
    141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  289. NG DZ, Tan WL, Ong WS, Gan EM, et al
    139PD: Lifetime incidence of brain metastases (BM) in EGFR-mutant (M+) lung cancer treated with first-line EGFR TKIs.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  290. PARK K, Tan EH, Zhang L, Hirsh V, et al
    140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  291. SCHULER M, Yang J, Sequist LV, Yamamoto N, et al
    138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  292. LENA H, Rizvi NA, Wolf J, Cappuzzo F, et al
    137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  293. AHN MJ, Yang J, Yu H, Saka H, et al
    136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  294. ROSELL R, Gettinger SN, Bazhenova LA, Langer CJ, et al
    1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  295. ROTHSCHILD SI, Zippelius A, Prince SS, Gonzalez M, et al
    129TiP: SAKK 16/14 - anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  296. EZE C, Roengvoraphoj O, Gerum S, Belka C, et al
    127P: Maximum treatment response and prophylactic cranial irradiation are important prognostic factors in limited disease small-cell lung cancer patients comprehensively staged with cranial magnetic resonance imaging.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  297. ISMAIL D
    128P: Cryosurgery for advanced stages of non small cell lung cancer (5 years experience).
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  298. BILLIET C, Peeters S, Decaluwe H, Vansteenkiste J, et al
    126P: Outcome after post-operative radiotherapy (PORT) in ypN2 or R1/R2 versus no PORT in ypN0 stage III-N2 non-small cell lung cancer after induction chemotherapy and resection.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  299. DJURAEV F, Davidov R
    125P: Comparison efficacy of preoperative chemotherapy and surgery with surgery alone in patients with stage IIIA non-small-cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  300. GONG Y, Wang S, Xu Y, Wang J, et al
    124P: Acute severe radiation pneumonitis in post-operation radiation therapy among patients with lung cancer: An analysis of dose-volume parameters.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  301. APPEL S, Lawrence YR, Bar J, Nun AB, et al
    122P: Concomitant chemo-radiation to 60 Gy followed by surgery for locally advanced non-small cell lung cancer patients; evaluation of trimodality strategy.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  302. ROENGVORAPHOI O, Wijaya C, Eze C, Fendler W, et al
    123P: Impact of the primary tumor metabolic volume (PT-MV) changes in the course of multimodality treatment on overall survival in patients with locally-advanced non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  303. AYRE G, Casswell G, Comins C, Falk S, et al
    121P: Survival following treatment of non-small cell lung cancer (NSCLC) using continuous hyperfractionated accelerated radiotherapy (CHART): A single-centre retrospective analysis.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  304. SINWER RK, Kumar HS, Paramanandhan M, Purohit R, et al
    120P: Neoadjuvant chemotherapy followed by either continuous hyper-fractionated accelerated radiation therapy week-end less or conventional chemo-radiotherapy in locally advanced non small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  305. HE J, Zeng Z, Shi S
    119P: Feasibility and efficacy of helical IMRT for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  306. HENDRIKS L, Brouns A, Amini M, Uyterlinde W, et al
    115PD: Brain metastases (BM) development after chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter?
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  307. TEKATLI H, Haasbeek N, Dahele M, Haan Pd, et al
    116PD: Short-course, high-dose image-guided radiotherapy in poor risk patients with very central non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  308. POMARES AH, Maravilla EM, Lafuente B, Calabuig-Farinas S, et al
    114P: Expression analysis of tumorspheres from non-small cell lung cancer show significant differences in CSC-markers and signaling pathways.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  309. LEE JH, Min SK, Choi JE, Hong MJ, et al
    111P: Deltex-1 single nucleotide polymorphism rs1732786A>G is associated with the prognosis of surgically resected non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  310. LIU YN, Shen D, Sun KL
    112P: Macrophage inhibitory cytokine-1 as a biomarker for diagnosis and prognosis of stage I-II non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  311. CHUDAK C, Herrmann J, Lesser T
    113P: Enumeration and molecular characterization of circulating tumor cells in lung cancer patients using the GILUPI CellCollector.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  312. KOSE F, Findikcioglu A, Canpolat T, Sedef AM, et al
    110P: Predictive and prognostic role of T-regulatory cells in resected non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  313. CHOI JE, Do SK, Hong MJ, Lee JH, et al
    108P: Genetic polymorphisms in glycolytic pathway are associated with the prognosis of patients with early stage non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  314. UMAPATHY G
    109P: ALK activates ERK5, in both neuroblastoma and lung cancer - a putative therapeutic target in cancer treatment.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  315. HE J, Zeng Z, Shi S
    105P: Risk factors associated with symptomatic radiation pneumonitis after stereotactic body radiation therapy for stage I non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  316. HONG MJ, Choi JE, Do SK, Lee JH, et al
    107P: A functional polymorphism located in intron of EGFR affects survival outcome of early-stage non-small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  317. CHANG Y, Cho D, Cho K
    106P: Prognostic impact of incomplete interlober fissure in early stage lung cancer patients who underwent thoracoscopic lobectomy.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  318. ZANETTI IB, Scanagatta P, Bianchi LC, Bergantin A, et al
    102P: Ablative robotic radiosurgery for inoperable patients with stage IA-IB non small cell lung cancer.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  319. PANAGIOTOPOULOS N, Patrini D, Cabanyes SD, Hayward M, et al
    103P: Lobectomy for non-small cell lung cancer in octogenarians: A 7-year single center experience.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  320. ZHENG X, Ren Y, Ge W
    104P: Stereotactic body radiation therapy in early-stage non-small cell lung cancer in elderly patients: Safety and efficacy.
    J Thorac Oncol. 2016;11.
    PubMed     Text format    


  321. REKHTMAN N
    Molecular Assessment of Multiple Pulmonary Carcinomas: An Evolving Area.
    J Thorac Oncol. 2016;11:e54.
    PubMed     Text format    


  322. MARCHETTI A, Di Lorito A, Pace MV, Iezzi M, et al
    ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
    J Thorac Oncol. 2016;11:487-95.
    PubMed     Text format     Abstract available


  323. HWANG DH, Sholl LM, Rojas-Rudilla V, Hall DL, et al
    KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
    J Thorac Oncol. 2016;11:496-503.
    PubMed     Text format     Abstract available


  324. BRIMS FJ, Meniawy TM, Duffus I, de Fonseka D, et al
    A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.
    J Thorac Oncol. 2016;11:573-82.
    PubMed     Text format     Abstract available


  325. DERKS JL, van Suylen RJ, Thunnissen E, den Bakker MA, et al
    A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors.
    J Thorac Oncol. 2016;11:593-602.
    PubMed     Text format     Abstract available


  326. RIGHI L, Vatrano S, Di Nicolantonio F, Massa F, et al
    Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung.
    J Thorac Oncol. 2016;11:504-15.
    PubMed     Text format     Abstract available


  327. DICKHOFF C, Dahele M, de Langen AJ, Paul MA, et al
    Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013.
    J Thorac Oncol. 2016;11:566-72.
    PubMed     Text format     Abstract available


  328. JUKNA A, Montanari G, Mengoli MC, Cavazza A, et al
    Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.
    J Thorac Oncol. 2016;11:e49-51.
    PubMed     Text format     Abstract available


  329. CHAFT JE, Dunphy M, Naidoo J, Travis WD, et al
    Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.
    J Thorac Oncol. 2016;11:537-44.
    PubMed     Text format     Abstract available


  330. DONG A, Bai C, Zuo C
    Diffuse Pleural Myeloid Sarcoma Mimicking Malignant Mesothelioma.
    J Thorac Oncol. 2016;11:603-5.
    PubMed     Text format    


  331. LIN JJ, Cardarella S, Lydon CA, Dahlberg SE, et al
    Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
    J Thorac Oncol. 2016;11:556-65.
    PubMed     Text format     Abstract available


    March 2016
  332. TSAO AS, Scagliotti GV, Bunn PA Jr, Carbone DP, et al
    Scientific Advances in Lung Cancer 2015.
    J Thorac Oncol. 2016 Mar 21. pii: S1556-0864(16)30022.
    PubMed     Text format     Abstract available


  333. TEKATLI H, Haasbeek N, Dahele M, De Haan P, et al
    Outcomes of hypo-fractionated high dose radiotherapy in poor risk patients with "ultra-central" non-small cell lung cancer.
    J Thorac Oncol. 2016 Mar 21. pii: S1556-0864(16)30018.
    PubMed     Text format     Abstract available


  334. SALAZAR MC, Rosen JE, Arnold BN, Thomas DC, et al
    Adjuvant Chemotherapy for T3 Non-Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe.
    J Thorac Oncol. 2016 Mar 21. pii: S1556-0864(16)30019.
    PubMed     Text format     Abstract available


  335. KULKARNI S, Vella ET, Coakley N, Cheng S, et al
    The Use of Systemic Treatment in the Maintenance of Patients with Non-small Cell Lung Cancer: A Systematic Review.
    J Thorac Oncol. 2016 Mar 21. pii: S1556-0864(16)30017.
    PubMed     Text format     Abstract available


  336. AGGARWAL A, Lewison G, Idir S, Peters M, et al
    The state of lung cancer research: a global analysis.
    J Thorac Oncol. 2016 Mar 21. pii: S1556-0864(16)30020.
    PubMed     Text format     Abstract available


  337. GAINOR JF, Niederst MJ, Lennerz JK, Dagogo-Jack I, et al
    Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.
    J Thorac Oncol. 2016 Mar 14. pii: S1556-0864(16)00455.
    PubMed     Text format    


  338. LI Y, Zhang R, Peng R, Ding J, et al
    Brief Report: Reliability assurance of EML4-ALK rearrangement detection in non-small cell lung cancer: the results of a proficiency testing in China.
    J Thorac Oncol. 2016 Mar 14. pii: S1556-0864(16)00456.
    PubMed     Text format     Abstract available


  339. SINESHAW HM, Wu XC, Flanders WD, Osarogiagbon RU, et al
    Variations in Receipt of Curative-Intent Surgery for Early-Stage Non-Small Cell Lung Cancer (NSCLC) by State.
    J Thorac Oncol. 2016 Mar 12. pii: S1556-0864(16)00447.
    PubMed     Text format     Abstract available


  340. AGMON IN, Abud M, Liran O, Gai-Mor N, et al
    Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer.
    J Thorac Oncol. 2016 Mar 8. pii: S1556-0864(16)00440.
    PubMed     Text format     Abstract available


  341. RITCHIE AJ, Sanghera C, Jacobs C, Zhang W, et al
    Computer Vision Tool and Technician as First Reader of Lung Cancer Screening CT Scans.
    J Thorac Oncol. 2016 Mar 5. pii: S1556-0864(16)00360.
    PubMed     Text format     Abstract available


  342. HENDRIKS LE, Dingemans AM, De Ruysscher D
    Proposals for the M-descriptors of the Eight TNM Classification for Non-Small Cell Lung Cancer: Are More Data Needed?
    J Thorac Oncol. 2016;11:e42-3.
    PubMed     Text format    


  343. SHUKUYA T, Carbone DP
    Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer.
    J Thorac Oncol. 2016 Mar 1. pii: S1556-0864(16)00438.
    PubMed     Text format     Abstract available


  344. DETTERBECK FC, Franklin WA, Nicholson AG, Girard N, et al
    The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
    J Thorac Oncol. 2016 Mar 1. pii: S1556-0864(16)00437.
    PubMed     Text format     Abstract available


  345. EBERHARDT WE, Mitchell A, Rami-Porta R
    Reply to the Letter to the Editor by Hendriks et al.
    J Thorac Oncol. 2016;11:e43-4.
    PubMed     Text format    


  346. MACBETH F, Russell C, Treasure T
    Cryotherapy for Lung Metastases: A Procedure That Deserves Evaluation in a Randomized Trial.
    J Thorac Oncol. 2016;11:e41.
    PubMed     Text format    


  347. OPITZ I, Weder W
    Clinical Relevance of Our Multimodality Prognostic Score.
    J Thorac Oncol. 2016;11:e39-40.
    PubMed     Text format    


  348. KATAOKA Y, Tsujimoto H, Tsujimoto Y
    How Can We Use the Multimodality Prognostic Score?
    J Thorac Oncol. 2016;11:e39.
    PubMed     Text format    


  349. REUNGWETWATTANA T, Ou SH
    Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations.
    J Thorac Oncol. 2016;11:281-3.
    PubMed     Text format    


  350. DE RUYSSCHER D, Vansteenkiste J, Belderbos J, Decaluwe H, et al
    The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled?
    J Thorac Oncol. 2016;11:284-6.
    PubMed     Text format    


  351. WANG J, Shivakumar S, Barker K, Tang Y, et al
    Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
    J Thorac Oncol. 2016;11:334-45.
    PubMed     Text format     Abstract available


  352. DE KOCK L, Bah I, Wu Y, Xie M, et al
    Germline and Somatic DICER1 Mutations in a Well-Differentiated Fetal Adenocarcinoma of the Lung.
    J Thorac Oncol. 2016;11:e31-3.
    PubMed     Text format     Abstract available


  353. LEE H, Jeong SH, Jeong BH, Park HY, et al
    Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis.
    J Thorac Oncol. 2016;11:426-31.
    PubMed     Text format     Abstract available


  354. ZHANG YA, Ma X, Sathe A, Fujimoto J, et al
    Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
    J Thorac Oncol. 2016;11:346-60.
    PubMed     Text format     Abstract available


  355. LI BT, Ross DS, Aisner DL, Chaft JE, et al
    HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
    J Thorac Oncol. 2016;11:414-9.
    PubMed     Text format     Abstract available


  356. DERKS JL, Speel EJ, Thunnissen E, van Suylen RJ, et al
    Neuroendocrine Cancer of the Lung: A Diagnostic Puzzle.
    J Thorac Oncol. 2016;11:e35-8.
    PubMed     Text format     Abstract available


  357. GAZDAR AF, Hirsch FR, Minna JD
    From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.
    J Thorac Oncol. 2016;11:287-99.
    PubMed     Text format     Abstract available


    February 2016
  358. DETTERBECK FC, Bolejack V, Arenberg DA, Crowley J, et al
    The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2016 Feb 29. pii: S1556-0864(16)00433.
    PubMed     Text format     Abstract available


  359. DETTERBECK FC, Nicholson AG, Franklin WA, Marom EM, et al
    The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification.
    J Thorac Oncol. 2016 Feb 29. pii: S1556-0864(16)00431.
    PubMed     Text format     Abstract available


  360. DETTERBECK FC, Marom EM, Arenberg DA, Franklin WA, et al
    The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic-Type of Involvement in the Forthcoming Eig
    J Thorac Oncol. 2016 Feb 29. pii: S1556-0864(16)00432.
    PubMed     Text format     Abstract available


  361. JANNE PA, Shaw AT, Camidge DR, Giaccone G, et al
    Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-small Cell Lung Cancer: Results of a Phase I Study.
    J Thorac Oncol. 2016 Feb 17. pii: S1556-0864(16)00362.
    PubMed     Text format     Abstract available


  362. ABOUDA M, Turki S, Charfi M, Triki M, et al
    Pulmonary hydatid cyst mimicking a lung cancer.
    J Thorac Oncol. 2016 Feb 17. pii: S1556-0864(16)00406.
    PubMed     Text format    


  363. TAKENAKA T, Yamazaki K, Miura N, Mori R, et al
    The Prognostic Impact of Tumor Volume in Patients with Clinical Stage IA Non-small Cell Lung Cancer.
    J Thorac Oncol. 2016 Feb 17. pii: S1556-0864(16)00405.
    PubMed     Text format     Abstract available


  364. MA X, Le Teuff G, Lacas B, Tsao MS, et al
    Prognostic and predictive effect of TP53 mutations in non-small cell lung cancer patients from adjuvant cisplatin-based therapy randomized trials: a LACE-bio pooled analysis.
    J Thorac Oncol. 2016 Feb 16. pii: S1556-0864(16)00359.
    PubMed     Text format     Abstract available


  365. LOUIS E, Adriaensens P, Guedens W, Bigirumurame T, et al
    Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma.
    J Thorac Oncol. 2016 Feb 13. pii: S1556-0864(16)00334.
    PubMed     Text format     Abstract available


  366. ALEXANDER M, Evans SG, Burbury K, Stirling RG, et al
    The influence of comorbidity and the Simplified Comorbidity Score (SCS) on overall survival in non-small cell lung cancer - a prospective cohort study.
    J Thorac Oncol. 2016 Feb 3. pii: S1556-0864(16)00353.
    PubMed     Text format     Abstract available


  367. YANG P, Wang Y, Wampfler JA, Xie D, et al
    Trends in Subpopulations at High Risk for Lung Cancer.
    J Thorac Oncol. 2016;11:194-202.
    PubMed     Text format     Abstract available


  368. MURRAY N, Lam S
    Contrasting Management of Small Cell Lung Cancer and Non-Small Cell Lung Cancer: Emerging Data for Low-Dose Computed Tomography Screening.
    J Thorac Oncol. 2016;11:139-41.
    PubMed     Text format    


  369. GAINOR JF, Chi AS, Logan J, Hu R, et al
    Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.
    J Thorac Oncol. 2016;11:256-60.
    PubMed     Text format     Abstract available


  370. WONG AT, Rineer J, Schwartz D, Schreiber D, et al
    Assessing the Impact of Postoperative Radiation Therapy for Completely Resected Limited-Stage Small Cell Lung Cancer Using the National Cancer Database.
    J Thorac Oncol. 2016;11:242-8.
    PubMed     Text format     Abstract available


  371. SILVA M, Galeone C, Sverzellati N, Marchiano A, et al
    Screening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer.
    J Thorac Oncol. 2016;11:187-93.
    PubMed     Text format     Abstract available


  372. ZHOU C, Yao LD
    Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature.
    J Thorac Oncol. 2016;11:174-86.
    PubMed     Text format     Abstract available


  373. AZPILIKUETA A, Agorreta J, Labiano S, Perez-Gracia JL, et al
    Successful Immunotherapy Against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    J Thorac Oncol. 2016 Feb 1. pii: S1556-0864(16)00350.
    PubMed     Text format     Abstract available


  374. BREMNES RM, Busund LT, Kilvaer TL, Andersen S, et al
    The role of tumor infiltrating lymphocytes in development, progression and prognosis of non-small cell lung cancer.
    J Thorac Oncol. 2016 Feb 1. pii: S1556-0864(16)00352.
    PubMed     Text format     Abstract available


  375. TRAVIS WD, Brambilla E, Nicholson AG
    Testing for Neuroendocrine Immunohistochemical Markers Should Not Be Performed in Poorly Differentiated NSCCs in the Absence of Neuroendocrine Morphologic Features according to the 2015 WHO Classification.
    J Thorac Oncol. 2016;11:e26-7.
    PubMed     Text format    


  376. DERKS JL, Speel EJ, Dingemans AM
    An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers.
    J Thorac Oncol. 2016;11:e25-6.
    PubMed     Text format    


  377. VARESANO S, Salvi S, Boccardo S, Ravetti JL, et al
    MET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization.
    J Thorac Oncol. 2016;11:e28-30.
    PubMed     Text format    


  378. BENDERRA MA, Aspeslagh S, Postel-Vinay S, Bigot L, et al
    Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
    J Thorac Oncol. 2016;11:e21-3.
    PubMed     Text format    


  379. DELANOTE I, Budts W, De Leyn P, Dooms C, et al
    Large Bronchopleural Fistula After Surgical Resection: Secret to Success.
    J Thorac Oncol. 2016;11:268-9.
    PubMed     Text format    


  380. BILLE A, Krug LM, Woo KM, Rusch VW, et al
    Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2016;11:249-55.
    PubMed     Text format     Abstract available


  381. SUNAMI K, Furuta K, Tsuta K, Sasada S, et al
    Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
    J Thorac Oncol. 2016;11:203-12.
    PubMed     Text format     Abstract available


  382. KAMATA T, Sunami K, Yoshida A, Shiraishi K, et al
    Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung.
    J Thorac Oncol. 2016;11:261-5.
    PubMed     Text format     Abstract available


  383. NISHIYAMA A, Yoshioka H, Ikeo S, Morita M, et al
    Retroperitoneal Metastasis from Lung Adenocarcinoma Mimics Retroperitoneal Fibrosis.
    J Thorac Oncol. 2016;11:266-7.
    PubMed     Text format    


  384. DHILLON SS, Demmy TL, Yendamuri S, Loewen G, et al
    A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study.
    J Thorac Oncol. 2016;11:234-41.
    PubMed     Text format     Abstract available


    January 2016
  385. BUNN PA JR, Minna J, Augustyn A, Gazdar A, et al
    Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
    J Thorac Oncol. 2016 Jan 29. pii: S1556-0864(16)00335.
    PubMed     Text format    


  386. PELOSI G, Gasparini P, Conte D, Fabbri A, et al
    Synergic activation upon MET and ALK co-amplification sustains targeted therapy in sarcomatoid carcinoma, a deadly subtype of lung cancer.
    J Thorac Oncol. 2016 Jan 21. pii: S1556-0864(16)00329.
    PubMed     Text format     Abstract available


  387. SIMO M, Vaquero L, Ripolles P, Guturbay A, et al
    Longitudinal Brain Changes Associated with Prophylactic Cranial Irradiation in Lung Cancer.
    J Thorac Oncol. 2016 Jan 21. pii: S1556-0864(16)00330.
    PubMed     Text format     Abstract available


  388. SCHULER M, Wu YL, Hirsh V, O'Byrne K, et al
    First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    J Thorac Oncol. 2016 Jan 20. pii: S1556-0864(15)00220.
    PubMed     Text format     Abstract available


  389. KLUGHAMMER B, Brugger W, Cappuzzo F, Ciuleanu T, et al
    Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer Whose Tumors Harbor Uncommon Epidermal Growth Factor Receptors Mutations.
    J Thorac Oncol. 2016 Jan 7. pii: S1556-0864(16)00283.
    PubMed     Text format     Abstract available


  390. FUJITA S, Masago K, Katakami N, Yatabe Y, et al
    Transformation to small cell lung cancer following treatment with an ALK inhibitor, Alectinib.
    J Thorac Oncol. 2016 Jan 2. pii: S1556-0864(15)00275.
    PubMed     Text format     Abstract available


  391. OSAROGIAGBON RU, Lin CC, Smeltzer MP, Jemal A, et al
    Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.
    J Thorac Oncol. 2016;11:e5-e16.
    PubMed     Text format     Abstract available


  392. HAM JS, Kim S, Kim HK, Byeon S, et al
    Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.
    J Thorac Oncol. 2016;11:e1-4.
    PubMed     Text format    


  393. BELLI A, De Luca G, Bianco F, De Franciscis S, et al
    An Unusual Metastatic Site for Primary Lung Cancer: The Spleen.
    J Thorac Oncol. 2016;11:128-9.
    PubMed     Text format    


  394. MICHELS S, Scheel AH, Scheffler M, Schultheis AM, et al
    Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
    J Thorac Oncol. 2016;11:122-7.
    PubMed     Text format     Abstract available


  395. LIM C, Sung M, Shepherd FA, Nouriany N, et al
    Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?
    J Thorac Oncol. 2016;11:79-84.
    PubMed     Text format     Abstract available


  396. IKEDA S, Okamoto T, Okano S, Umemoto Y, et al
    PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016;11:62-71.
    PubMed     Text format     Abstract available


  397. LIU Y, Kheradmand F, Davis CF, Scheurer ME, et al
    Focused Analysis of Exome Sequencing Data for Rare Germline Mutations in Familial and Sporadic Lung Cancer.
    J Thorac Oncol. 2016;11:52-61.
    PubMed     Text format     Abstract available


  398. GOLDSTRAW P, Chansky K, Crowley J, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2016;11:39-51.
    PubMed     Text format     Abstract available


  399. RODIN D, Grover S, Xu MJ, Hanna TP, et al
    Radiotherapeutic Management of Non-Small Cell Lung Cancer in the Minimal Resource Setting.
    J Thorac Oncol. 2016;11:21-9.
    PubMed     Text format     Abstract available


  400. DESAI A, Adjei AA
    FGFR Signaling as a Target for Lung Cancer Therapy.
    J Thorac Oncol. 2016;11:9-20.
    PubMed     Text format     Abstract available


  401. LOHINAI Z, Ostoros G, Moldvay J, Dome B, et al
    Differences in the Epidemiology of Rare EGFR Mutations in Different Populations.
    J Thorac Oncol. 2016;11:e19-20.
    PubMed     Text format    


  402. ELGHISSASSI I, Boutayeb S, Errihani H
    The Frequency of Rare EGFR Mutations Is Higher than that of Classical Ones: How Come?
    J Thorac Oncol. 2016;11:e17.
    PubMed     Text format    


  403. GREILLIER L, Tounsi A, Berenguer-Daize C, Dussault N, et al
    Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2016;11:94-107.
    PubMed     Text format     Abstract available


  404. KREUTER M, Vansteenkiste J, Fischer JR, Eberhardt WE, et al
    Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
    J Thorac Oncol. 2016;11:85-93.
    PubMed     Text format     Abstract available


  405. MAZZONE PJ, Wang XF, Beukemann M, Zhang Q, et al
    Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
    J Thorac Oncol. 2016;11:72-8.
    PubMed     Text format     Abstract available


  406. ADJEI AA
    The Journal of Thoracic Oncology in the Next Decade.
    J Thorac Oncol. 2016;11:8.
    PubMed     Text format    


    December 2015
  407. SONG HN, Jung KS, Yoo KH, Cho J, et al
    Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2015 Dec 31. pii: S1556-0864(15)00209.
    PubMed     Text format     Abstract available


  408. ZER A, Ding K, Lee SM, Goss GD, et al
    Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2015 Dec 31. pii: S1556-0864(15)00203.
    PubMed     Text format     Abstract available


  409. TAIOLI E, Yip R, Olkin I, Wolf A, et al
    Survival After Sublobar Resection for Early-Stage Lung Cancer: Methodological Obstacles in Comparing the Efficacy to Lobectomy.
    J Thorac Oncol. 2015 Dec 31. pii: S1556-0864(15)00044.
    PubMed     Text format     Abstract available


  410. KARASAKI T, Nagayama K, Kawashima M, Hiyama N, et al
    Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
    J Thorac Oncol. 2015 Dec 29. pii: S1556-0864(15)00076.
    PubMed     Text format     Abstract available


  411. LARA PN JR, Moon J, Hesketh PJ, Redman MW, et al
    SWOG S0709: Randomized Phase II Trial of Erlotinib Versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.
    J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00051.
    PubMed     Text format     Abstract available


  412. YANG JC, Srimuninnimit V, Ahn MJ, Lin CC, et al
    First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results
    J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00108.
    PubMed     Text format     Abstract available


  413. MCCOACH CE, Berge EM, Lu X, Baron AE, et al
    A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry.
    J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00047.
    PubMed     Text format     Abstract available


  414. NICHOLSON AG, Chansky K, Crowley J, Beyruti R, et al
    The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Ca
    J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00030.
    PubMed     Text format     Abstract available


  415. SALAMA JK, Gu L, Wang X, Pang HH, et al
    Positive Interaction Between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
    J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00049.
    PubMed     Text format     Abstract available


  416. HENDRIKS LE, Hermans BC, van den Beuken-van Everdingen MH, Hochstenbag MM, et al
    Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer Patients and Bone Metastases: A Systematic Review.
    J Thorac Oncol. 2015 Dec 22. pii: S1556-0864(15)00012.
    PubMed     Text format     Abstract available


  417. MEHMOOD Q, Sun A, Becker N, Higgins J, et al
    Predicting Radiation Esophagitis Using F-FDG PET During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2015 Dec 22. pii: S1556-0864(15)00028.
    PubMed     Text format     Abstract available


  418. MEDBERY RL, Gillespie TW, Liu Y, Nickleach DC, et al
    Nodal Upstaging Is More Common with Thoracotomy than with VATS During Lobectomy for Early-Stage Lung Cancer: An Analysis From the National Cancer Data Base.
    J Thorac Oncol. 2015 Dec 18. pii: S1556-0864(15)00029.
    PubMed     Text format     Abstract available


  419. RAMI-PORTA R, Bolejack V
    Reply to "Inclusion of Lymphangitis as a Descriptor in the New TNM Staging of Lung Cancer: Filling Up the Blank Spaces".
    J Thorac Oncol. 2015;10:e119-20.
    PubMed     Text format    


  420. SINGH N, Baldi M, Behera D
    Inclusion of Lymphangitis as a Descriptor in the New TNM Staging of Lung Cancer: Filling Up the Blank Spaces.
    J Thorac Oncol. 2015;10:e119.
    PubMed     Text format    


  421. LEE C, Usenko D, Frampton GM, McMahon C, et al
    MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor.
    J Thorac Oncol. 2015;10:e113-4.
    PubMed     Text format    



  422. Increasing Physical Activity and Exercise in Lung Cancer: Reviewing Safety, Benefits, and Application: Erratum.
    J Thorac Oncol. 2015;10:1712.
    PubMed     Text format    


  423. ASAMURA H, Chansky K, Crowley J, Goldstraw P, et al
    The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2015;10:1675-84.
    PubMed     Text format     Abstract available


  424. PAZ-ARES L, Hirsh V, Zhang L, de Marinis F, et al
    Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung
    J Thorac Oncol. 2015;10:1745-53.
    PubMed     Text format     Abstract available


    November 2015
  425. FARAGO AF, Le LP, Zheng Z, Muzikansky A, et al
    Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2015.
    PubMed     Text format     Abstract available


    September 2015

  426. 16th World Conference on Lung Cancer.
    J Thorac Oncol. 2015;10.
    PubMed     Text format    


    August 2015
  427. ROGERS TM, Fox SB
    In Response.
    J Thorac Oncol. 2015;10:e85.
    PubMed     Text format    


  428. ZHAO H, Zhang L
    Reply: To PMID 25546556.
    J Thorac Oncol. 2015;10:e82-3.
    PubMed     Text format    


    May 2015

  429. In Memoriam. Mark R. Green, MD (1945-2015).
    J Thorac Oncol. 2015;10:729-30.
    PubMed     Text format    


  430. DIETRICH MF, Yan SX, Schiller JH
    Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung.
    J Thorac Oncol. 2015;10:e23-5.
    PubMed     Text format     Abstract available


  431. MENDENHALL MA, Goldman JW
    MET-Mutated NSCLC with Major Response to Crizotinib.
    J Thorac Oncol. 2015;10:e33-4.
    PubMed     Text format    


  432. WAQAR SN, Morgensztern D, Sehn J
    MET Mutation Associated with Responsiveness to Crizotinib.
    J Thorac Oncol. 2015;10:e29-31.
    PubMed     Text format    


  433. MURAKAMI Y, Saka H, Oki M
    Response to Crizotinib and Clinical Outcome in ALK-Rearranged Pulmonary Pleomorphic Carcinoma.
    J Thorac Oncol. 2015;10:e28-9.
    PubMed     Text format    


  434. ABE H, Kawahara A, Azuma K, Taira T, et al
    Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.
    J Thorac Oncol. 2015;10:800-5.
    PubMed     Text format     Abstract available


    April 2015
  435. SU YL, Rau KM
    Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.
    J Thorac Oncol. 2015;10:e21-2.
    PubMed     Text format    


  436. ROBINSON B, Geneva I, Landas S, Michiel R, et al
    Novel association of elastofibroma with aortic stenosis: report of a case report interfering with a thoracotomy procedure and a reassessment of typical patient demographics and tumor location.
    J Thorac Oncol. 2015;10:e18-20.
    PubMed     Text format    


  437. BRINJIKJI W, Boland Froemming JM, Holland WP, Peikert T, et al
    Unexpectedly fludeoxyglucose (18F) avid well-differentiated adenocarcinoma of the lung.
    J Thorac Oncol. 2015;10:719-20.
    PubMed     Text format    


  438. PICIUCCHI S, Gurioli C, Barone D, Gurioli C, et al
    Life-threatening bronchomediastinal fistula complicating a first cycle of chemotherapy in a stage IV NSCLC case.
    J Thorac Oncol. 2015;10:717-8.
    PubMed     Text format    


  439. GRUBER K, Kohlhaufl M, Friedel G, Ott G, et al
    A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry.
    J Thorac Oncol. 2015;10:713-6.
    PubMed     Text format     Abstract available


  440. YATABE Y
    ALK FISH and IHC: you cannot have one without the other.
    J Thorac Oncol. 2015;10:548-50.
    PubMed     Text format    


  441. MACK PC
    Plasma-based tumor genetics for monitoring disease progression: what can we learn from a tube of blood?
    J Thorac Oncol. 2015;10:546-7.
    PubMed     Text format    


  442. GAZDAR AF, Savage TK, Johnson JE, Berns A, et al
    The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.
    J Thorac Oncol. 2015;10:553-64.
    PubMed     Text format     Abstract available


  443. NASU M, Emi M, Pastorino S, Tanji M, et al
    High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
    J Thorac Oncol. 2015;10:565-76.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: